CAJ | 학술논문

HCV感染可导致慢性丙型肝炎(CHC),通常采用聚乙二醇IFN联合利巴韦林进行标准化治疗.近年,随着蛋白酶抑制剂的问世,三联疗法呈现良好的抗HCV能力,同时给不能耐受或不适合IFN治疗的患者带来了希望.HCV NS3/4A蛋白酶在病毒体成熟和复制过程中具有重要地位,而蛋白酶抑制剂有广阔的应用前景,此文综述了HCV NS3/4A蛋白酶的结构特点及其抑制剂的研究进展.
HCV감염가도치만성병형간염(CHC),통상채용취을이순IFN연합리파위림진행표준화치료.근년,수착단백매억제제적문세,삼련요법정현량호적항HCV능력,동시급불능내수혹불괄합IFN치료적환자대래료희망.HCV NS3/4A단백매재병독체성숙화복제과정중구유중요지위,이단백매억제제유엄활적응용전경,차문종술료HCV NS3/4A단백매적결구특점급기억제제적연구진전.
Pegylated interferon (PEG-IFN) and ribavirin(RBV) are regarded as the standardized treatment for chronic hepatitis C (CHC) which is caused by HCV infection.In recent years,with the development of protease inhibitors (PIs),triple therapy has shown good antiviral ability,and brings hope for patients who cannot tolerate or accommodate to IFN therapy.Based on the importance of NS3/4A protease in virus maturation and replication processes,and the wide prospect of protease inhibitors,the structural characteristics of HCV NS3/4A protease and its inhibitors are reviewed in this article.